Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      COVID-19/*epidemiology; Adult ; Aged ; Aged, 80 and over ; Amides/therapeutic use ; Antiviral Agents/therapeutic use ; Chloroquine/therapeutic use ; Darunavir/therapeutic use ; Disease Progression ; Drug Combinations ; Female ; Hospitals ; Hospitals, University ; Humans ; Hydroxychloroquine/therapeutic use ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Pyrazines/therapeutic use ; Referral and Consultation ; Retrospective Studies ; Ritonavir/therapeutic use ; Thailand/epidemiology ; Treatment Outcome ; Young Adult ; COVID-19 Drug Treatment
    • Abstract:
      Background: The epidemiology and outcomes of COVID-19 patients in Thailand are scarce.
      Methods: This retrospective cohort study included adult hospitalized patients who were diagnosed with COVID-19 at Siriraj Hospital during February 2020 to April 2020.
      Results: The prevalence of COVID-19 was 7.5% (107 COVID-19 patients) among 1409 patients who underwent RT-PCR for SARS-CoV-2 detection at our hospital during the outbreak period. Patients with COVID-19 presented with symptoms in 94.4%. Among the 104 patients who were treated with antiviral medications, 78 (75%) received 2-drug regimen (lopinavir/ritonavir or darunavir/ritonavir plus chloroquine or hydroxychloroquine), and 26 (25%) received a 3-drug regimen with favipiravir added to the 2-drug regimen. Disease progression was observed in 18 patients (16.8%). All patients with COVID-19 were discharged alive.
      Conclusions: The prevalence of COVID-19 was 7.5% among patients who underwent RT-PCR testing, and 10% among those having risk factors for COVID-19 acquisition. Combination antiviral therapies for COVID-19 patients were well-tolerated and produced a favorable outcome.
    • References:
      JAMA. 2020 Apr 7;323(13):1239-1242. (PMID: 32091533)
      Infection. 2020 Oct;48(5):687-694. (PMID: 32390091)
      Euro Surveill. 2020 Feb;25(8):. (PMID: 32127124)
      Emerg Infect Dis. 2020 Jul;26(7):. (PMID: 32364890)
      N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
      Clin Infect Dis. 2020 Apr 27;:. (PMID: 32338708)
      Emerg Infect Dis. 2020 Jul;26(7):1580-1585. (PMID: 32267826)
      N Engl J Med. 2020 Mar 12;382(11):1067-1068. (PMID: 32050060)
      J Intern Med. 2020 Aug;288(2):192-206. (PMID: 32348588)
      Am J Trop Med Hyg. 2020 May;102(5):940-942. (PMID: 32238223)
      JAMA. 2020 May 19;323(19):1966-1967. (PMID: 32232421)
      Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028. (PMID: 32286245)
      JAMA. 2020 Jun 9;323(22):2249-2251. (PMID: 32374370)
      JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. (PMID: 32936252)
      Clin Microbiol Infect. 2020 Jul;26(7):842-847. (PMID: 32344166)
    • Contributed Indexing:
      Keywords: COVID-19; Clinical characteristics; Epidemiology; Outcome; Thailand; Treatment
    • Accession Number:
      0 (Amides)
      0 (Antiviral Agents)
      0 (Drug Combinations)
      0 (Pyrazines)
      0 (lopinavir-ritonavir drug combination)
      2494G1JF75 (Lopinavir)
      4QWG6N8QKH (Hydroxychloroquine)
      886U3H6UFF (Chloroquine)
      EW5GL2X7E0 (favipiravir)
      O3J8G9O825 (Ritonavir)
      YO603Y8113 (Darunavir)
    • Publication Date:
      Date Created: 20210427 Date Completed: 20210428 Latest Revision: 20221207
    • Publication Date:
      20240105
    • Accession Number:
      PMC8072093
    • Accession Number:
      10.1186/s12879-021-06081-z
    • Accession Number:
      33902480